Qiagen (QGEN) – Research Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Qiagen (NYSE: QGEN):

• 12/22/2025 – Qiagen had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/21/2025 – Qiagen was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 12/15/2025 – Qiagen had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Qiagen had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $55.00 price target on the stock, up previously from $53.00.
• 12/13/2025 – Qiagen was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/11/2025 – Qiagen was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $50.00 price target on the stock, down previously from $55.00.
• 12/8/2025 – Qiagen had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Qiagen had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Qiagen had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Qiagen had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Qiagen had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/1/2025 – Qiagen was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.